The present study characterized in vitro metabolites of 20(R)- 12b, in mouse, rat, dog, monkey and human liver microsomes. 20(R)-25-OCH 3 -PPD was incubated with liver microsomes in the presence of NADPH. The reaction mixtures and the metabolites were identified on the basis of their mass profiles using LC-Q/TOF and were quantified using triple quadrupole instrument by multiple reaction monitoring. A total of 7 metabolites (M1-M7) of the phase I metabolites were detected in all species. 25(R)-OCH 3 -PPD was metabolized by hydroxylation, dehydrogenation, and O-demethylation. Enzyme kinetic of 20(R)-25-OCH 3 -PPD metabolism was evaluated in rat and human hepatic microsomes. Incubations studies with selective chemical inhibitors demonstrated that the metabolism of 20(R)-25-OCH 3 -PPD was primarily mediated by CYP3A4. We conclude that 20(R)-25-OCH 3 -PPD was metabolized extensively in mammalian species of mouse, rat, dog, monkey, and human. CYP3A4-catalyzed oxygenation metabolism played an important role in the disposition of 25(R)-OCH 3 -PPD, especially at the C-20 hydroxyl group.
Introduction
Panax ginseng, a traditional herbal medicine used in the Eastern Asia for more than 2000 years, is presently being used worldwide as one of the most common complementary alternative medicines [1] . Ginseng, the root of Panax ginseng, has various health benefits, ranging from overcoming fatigue to treating severe cardiac and cancer problems [2] [3] [4] [5] . 25-methoxydammarane-3, 12, 20-triol (25-OCH 3 -PPD) was a novel dammarane-type triterpene sapogenin that was first reported by Zhao [6, 7] , from the leaves of P.notoginseng. 25-OCH 3 -PPD exerts the strongest activity among any of the known ginsenosides tested for cytotoxic effects [8] . It is an effective inhibitor of cell growth and proliferation and inducer of apoptosis and cell cycle arrest. 25-OCH 3 -PPD had significant, dose-dependent effects on apoptosis, proliferation, and cell cycle progression. Preclinical data indicate that 25-OCH 3 -PPD is a potential therapeutic agent against prostate cancer [9] and human breast cancer through down-regulating MDM2 [10] . 25(R)-OCH 3 -PPD ( Figure 1 ) showed anti-lung cancer activity by activation of p38 MAPK pathway and generation of reactive oxygen species [11] .
20(S) and 20(R) forms of 25-OCH 3 -PPD are stereoisomers of each other that depend on the orientation of the C-20 hydroxyl.
During the preclinical evaluation, we found that 25(S)-OCH 3 -PPD could be absorbed with an absolute bioavailability of 19.7% 67.6% (10 mg/kg) in rats [12] . 25-OCH 3 -PPD was converted to 25-OH-PPD in rats after oral gavage or iv injection. 25(S)-OCH 3 -PPD was metabolized to form active 25-OH-PPD after oral and intravenous administration. Plasma level of 25-OH-PPD was greater than that of 25-OCH 3 -PPD. However, 25-OH-PPD was less active than parent compounds in vitro [6] . The pharmacoki- netic profiles of 25(R)-OCH 3 -PPD and 25(S)-OCH 3 -PPD were different. 25(R)-OCH 3 -PPD was absorbed less than that of 25(S)-OCH 3 -PPD in rats [13] .
It is important to examine whether or not 25(R)-OCH 3 -PPD was metabolized by drug-metabolizing enzyme(s) in liver microsomes and then attempted to elucidate human P450 isoform(s) responsible for the biotransformation of 25(R)-OCH 3 -PPD. The study of hepatic microsomal-mediated metabolism will be of great significance for understanding of their systematic disposition and of 25(R)-OCH 3 -PPD-drug interaction and the mechanisms involved.
The objectives of the present study were as follows: 1) to characterize the structures of oxidative metabolites of 25(R)-OCH 3 -PPD, 2) to examine the difference of metabolism of 25(R)-OCH 3 -PPD by rodent (mice and rats) and nonrodent (dogs and monkeys) animal species hepatic microsomes and 3) to identify the cytochrome P450 (P450) and non-P450 enzymes responsible for 25(R)-OCH 3 -PPD biotransformation. + , glucose-6-phosphate (G-6-P) and glucose-6-phosphate dehydrogenase (G-6-PDH) were purchased from Sigma-Aldrich (St.Louis, MO). All solvents used for high-performance liquid chromatography (HPLC) were of HPLC grade (Merck, Darmstadt, Germany). Chemical inhibitors, ketoconazole (Ket), anaphthoflavone (Naph), sulfaphenazole (Sul), quercetin (Que), quinidine (Qui),diethyl dithiocarbamate (DDC) and ticlopidine (TP) (purity .99%) were purchased from Sigma-Aldrich (Shanghai, China). Purified water was generated with a Milli-Q Gradient system (Millipore Corporation, Molsheim, France).
Materials and Methods

Reagents
Chromatography of 25(R)-OCH 3 -PPD and Metabolites
The Agilent 1200 HPLC system was equipped with a reversedphase column (Atlantis T3C 18 , 2.16150 mm i.d., 5 mm; Waters CA) protected by a 4.063.0 mm i.d. Security Guard (5 mm) C 18 guard column (Phenomenex, Torrance, CA). Mobile phases A and B consisted of 0.1% (volume fraction) formic acid in water and methanol, respectively. Gradient elution at a flow rate of 0.2 ml/ min was with the following program: initial 70% B for 3 min, increased to 95% in 14 min, maintaining this condition for 8 min, ramping back down to 70% B in 1 min and holding at this condition for a further 4 min, to give a total runtime of 30 min.
Mass Spectrometry
The initial screening of the compounds' metabolites and accurate mass measurements was carried out using Agilent liquid chromatography quadrupole -time -of-flight mass spectrometer (LC-Q/TOF) 6520 mass spectrometer. A generic positive electrospray ionization method was used for all substrates and metabolites. The capillary voltage was 3500 V, cone voltage 20 V, and desolvation and source temperatures 260 and 150uC, respectively. Nitrogen was used as the desolvation and cone gas with flow rates of 900 and 300 L/h. All data acquired were processed using Mass Hunter Qualitative Analysis Software (B.04.00, Agilent).
The quantification (multiple reaction monitoring, MRM) and fragmentation measurements were performed with Shimadzu LC-MS/MS-8030 triple quadrupole instrument following positive mode electrospray ionization (ESI). The capillary voltage was 4500 V, and desolvation and source temperatures 250 and 150uC, respectively. The collision gas was argon with a CID gas cell pressure of 2.0610 3 mbar. Nitrogen was used as the drying and nebulizing gas with flow rates of 90 and 15 L/h. The data generated was processed using Shimadzu LabSolutions version 5.
Metabolism by Human, Monkey, Dog, Rat, and Mouse Liver Microsomes 25(R)-OCH 3 -PPD were incubated in hepatic microsomes to examine the potential P450-mediated metabolism. Stock solutions of 2 mM 25(R)-OCH 3 -PPD was prepared in methanol. The final methanol concentration in the incubation was 2.5% (v/v). The liver microsomes were carefully thawed on ice before the experiment.
For NADPH dependent oxidative metabolism study, the reaction media contained 1 mg/ml of microsomal proteins, 10 mM G-6-P, 10 mM MgCl 2 , 1 U/ml G-6-PDH, 50 mM concentration of 25(R)-OCH 3 -PPD in potassium phosphate buffer (pH 7.4; 0.1 M) in a total volume of 200 ml. Negative control incubations containing no NADPH-regenerating system were conducted. All incubations were performed at 37uC in a shaking water bath for 60 min.
After 5 min preincubation at 37uC, the incubation reactions were initiated with the addition of microsome proteins. After undergoing incubation for 60 min, the reactions were terminated with an equal volume of ice-cold acetonitrile and 10 ml diazepam (5 mg/ml, internal standard) was added. This sample was vortexmixed and centrifuged at 14,000 g for 5 min. The supernatant was transferred into a glass tube, evaporated to dryness under a stream of nitrogen at 40uC. The residue was reconstituted in 100 ml of methanol with 0.1% formic acid, centrifuged 10 min at 18000 rpm and then an aliquot 5 mL of the supernatant was directly injected onto the HPLC-MS system for quanlitative or quantitative analysis.
Chemical Inhibition Study in Human Hepatic Microsomes
The chemical inhibition study was performed by adding each of the specific inhibitors of P450 enzymes into the incubation of 25(R)-OCH 3 -PPD (3 or 10 mM) in 0.25 mg/ml HLM incubation systems containing an NADPH-regenerations system as described above. The chemical inhibitors and concentration were selected on the basis of previous reports and are as follows: a-naphthoflavone (10.0 mM) for CYP1A2, quercetin (10 mM) for CYP2C8, sulfaphenazole (10.0 mM) for CYP2C9, ticlopidine (5 mM) for CYP2C19, quinidine (10.0 mM) CYP2D6, diethyl dithiocarbamate (20 mM) for CYP2E1, and ketoconazole (0.1, 0.25, 0.5, 1 and 5 mM) for CYP3A.
The inhibitors were dissolved in dimethyl sulfoxide, and the final concentration of dimethyl sulfoxide in the incubation was 1% (v/v). The final incubation volume was 200 ml. Microsomes were preincubated for 5 min with a NADPH-regenerating system at 
Recombinant Enzyme Incubations
25(R)-OCH 3 -PPD (3, 10 mM) was incubated in duplicate at 37uC for 30 min with a panel of recombinant human P450 enzymes CYP3A4, at 4 pmol/ml. NADPH-regenerations system was the same as part of metabolism by human, monkey, dog, rat, and mouse liver microsomes. Samples were prepared as previously described and an aliquot 5 ml was subjected to HPLC-MS/MS analysis to measure the metabolites formed. Parallel incubations without NADPH-regenerations system served as control. 
Statistical Analysis
All of the data reported represent the mean 6 standard deviation. All experiments were conducted at least twice. The ttest was used for the statistical data analysis and the level of significant was set at p-value of 0.05.
Results
Mass Spectral Properties of 25(R)-OCH 3 -PPD and Metabolites
A comprehensive understanding of the fragmentation behavior of the parent compound to be tested can be very helpful in metabolite identification using LC-Q/TOF. 25(R)-OCH 3 -PPD incubated with hepatic microsomes resulted in seven metabolites was detected from the extracted mass chromatograms, and 25(R)-OH-PPD was identified with the help of standards. Under the experimental conditions, the 25(R)-OCH 3 -PPD molecule (m/z 493) was detected under positive scan mode ( Figure 2A ) and m/z 515 was [M+Na] + . In the MS 2 spectrum (Figure 2B ), 25(R)-OCH 3 -PPD displayed diagnostic fragment ions were 475, 457, 443, 425, and 407. Figure 3 showed the spectrum of 25(R)-OH-PPD (m/z 479) was detected under positive scan mode ( Figure 3A ) and m/z 501 was [M+Na] + . In the MS 2 spectrum fragment ions were 461, 443, 425, 407 ( Figure 3B ). 
LC/MS/MS Analysis by Triple Quadrupole Mass Spectrometry
When 25(R)-OCH 3 -PPD was incubated without NADPH or microsomes, no metabolites were generated; indicating that there were no chemical reactions under the incubation conditions. Figure 4 showed extracted ion chromatograms of the parent drug and 7 metabolites after incubation in the human liver microsome. Table 1 showed the retention time, MS/MS fragment ions of 25 (R)-OCH 3 -PPD and its metabolites under the present conditions. The phase I metabolite profiles of 25(R)-OCH 3 -PPD were found in all species. Proposed in vitro metabolic pathways of 25(R)-OCH 3 -PPD in human and rat microsomes were shown in Figure 5 .
The quantification for 25(R)-OCH 3 -PPD was performed with the transitions of m/z 493.5R425.3 and m/z 479.5R425.3 for 20(R)-25-OH-PPD. Diazepam with the transition of m/z 285.0R154.0 was employed as an internal standard. The assessment of bioanalytical method validation has been described elsewhere [13, 14] . The other metabolites were only semiquantitated using the ratios of their peak areas relative to that of the internal standard. According to the character of metabolite by MRM in the positive mode was performed using the MS/MS fragment ions, m/z 493.3R439. 
Chemical Inhibition Study in Human Hepatic Microsomes
Among various specific chemical inhibitors were used, only ketoconazole showed a significant inhibitory effect on the oxidative metabolism of 25(R)-OCH 3 -PPD ( Figure 7) . All other P450 isoform-specific inhibitors resulted in a negligible effect on the oxygenation metabolism of 25(R)-OCH 3 -PPD. P450 3As were probably the major enzymes responsible for the oxidative metabolism of 25(R)-OCH 3 -PPD. As expected, the oxidative metabolites of 25(R)-OCH 3 -PPD were detected in the incubations only with CYP3A4. The phase I metabolite profile of 25(R)-OCH 3 -PPD in CYP3A4 was shown in Figure 8 . Table 2 showed summary of K m and V max values for metabolite formation in human liver microsome. Results from the inhibition of an enzymatic process can have serious implications for clinical drug therapy. Preliminary experiments were performed to ensure that the depletion of parent compound was in the linear range of both reaction time and protein concentration of microsomes. The apparent K m for M2, M5, M7 was,5 mM under our conditions; but the value K m for M1, M3, M4, M6 was 19-30 mM, and the V max value ranged from 11.3 (M2) to 165 (M4) pmol/min/mg protein.
Enzymatic Kinetics of 25(R)-OCH 3 -PPD Metabolism by HLM
Discussion
The possible cancer preventive activity of Panax notoginseng is receiving more and more attention. Information on the metabolism of Panax notoginseng components is important for understanding the biological effects of Panax notoginseng. Some reports concerned the structure-activity relationship and substrate-dependent phenomena in effects of Ginsenosides on P450 Enzymes [15, 16] . Previously, we reported the pharmacokinetics of 25(R)-OCH 3 -PPD in rat. Thus far, the differences in the metabolic pathways and behaviors of 25(R)-OCH 3 -PPD between human and common experimental animals have not been revealed. Hence, in this study a comparison of metabolic profiles, enzymes involved, and catalytic efficiency for 25(R)-OCH 3 -PPD metabolism in liver microsomes from different species was performed. The products of 25(R)-OCH 3 -PPD biotransformation with liver microsomes in vitro were first analyzed using LC-TOF-MS. We speculated structures of the metabolites in positive-ion mode on the fragment rules. Then, the parent compound and M1-M7 were quantified by LC/MS/MS performed on Shimadzu LC-MS/MS-8030 following positive mode electrospray ionization.
A total of 7 metabolites were identified based on the retention times, molecular weights, parent ions and fragment ions which are presented in Table 1 . The proposed metabolic pathways of 25(R)-OCH 3 -PPD in liver microsome were shown in Figure 5 . These metabolites may be classified into three types: demethylation (M1, M2, M3 and M5), dehydrogenation (M2 on base of M3), (M4 on base of M6) and hydroxylation (M6 on base of M0, M3 on base of M1, M5 on base of M2, M7 on base of M4). Future works need to confirm whether demethylation was formed from M6 to M3, M4RM2 and M7RM5. The methyl group was easily removed by phase I enzymes and hydroxylation derivatives were the main metabolites.
We were only able to investigate the metabolites M2-M7 by semi-quantitated method due to the lack of authentic standards. The intrinsic clearance (V max /K m ) ranked as follows: M3, M1, M6, M5, M4, M2, M7 (Table 2) . It was necessary to address the observed discrepancies of catalytic efficiencies among the animal liver microsomes. The study revealed a comparative metabolism of 25(R)-OCH 3 -PPD in liver microsomes from mouse, rat, dog, monkey, and human. The metabolites were similar across all animal species, with a few distinct differences in amount ( Figure 6 ).
Metabolite M1 was the dominant metabolite from the rodent species after incubation of 25(R)-OCH 3 -PPD with microsomes, was found in an intermediate relative amount in dog, and was a minor metabolite in monkey and human microsomes. In addition M3 and M5 were the major product of 25(R)-OCH 3 -PPD metabolism in HLM, but a very minor product of incubation from microsomes of MLM and in dog. However, the more metabolites M4 and M7 were found in all species. In particular, M5 was the major metabolite in CyLM and HLM under our experimental parameters, while this compound was minor in all other species, with the smallest amount produced from DLM incubation.
For further exploration of the similarity of the enzymes responsible for the metabolism of 25(R)-OCH 3 -PPD from various species, chemical inhibition studies with selective general inhibitors were administrated. Ketoconazole inhibited the formation of M2, M3, M4, M5, M7 and showed concentration dependent ( Figure 7) . Ketoconazole inhibited the formation of M5 completely at concentration of 0.1 mM. Ketoconazole (0.1-1 mM) activated formation of M1 and M6, but at 5 mM inhibited the formation of M1 and M6. The reason is that M1 and M6 were not sensitive to ketoconazole.
Both chemical inhibition studies and recombinant enzyme screen results showed that CYP3A4 was the major P450 isoform in formation of all oxidative metabolites of 25(R)-OCH 3 -PPD and M7 was with the largest amount among the metabolites. Previous work by Li et al [16] demonstrated that CYP3A4 contributed to the formation of all oxidative metabolites of Rh2. Rh2 is also a dammarane-type triterpenoid saponin formed by a glucose sugar moiety glycosidically bonded to the hydroxy group at the C-3 position of 20(S)-protopanaxadiol (PPD). The inhibition of the CYP3A4 catalytic activity by 25(R)-OCH 3 -PPD was NADPH and concentration-dependent, which supplies a possible explanation for the low absorption of 25(R)-OCH 3 -PPD in rats in our previous research.
